Physician profile
William A Wray
NPI 1245209394
$6,163.70
in general payments reported to CMS, 2019-2025
21 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $140 · 2021: $420 · 2022: $701 · 2023: $1,064 · 2024: $1,723 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622 · Education: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.26 |
| Education | $512.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,900.30 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,441.04 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $649.41 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $314.76 | 2019-2025 | Olumiant, Ebglyss |
| Pfizer INC. | $305.00 | 2019-2025 | |
| Galderma Laboratories, L.P. | $266.27 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $252.05 | 2019-2025 | Dupixent |
| Amgen INC. | $229.45 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $139.70 | 2023 | Sotyktu |
| Genzyme Corporation | $124.41 | 2020-2024 | |
| Leo Pharma INC. | $99.05 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.25 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $67.79 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $65.66 | 2024 | |
| Incyte Corporation | $56.79 | 2021-2024 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.35 | 2019-2025 | Siliq, Cabtreo |
| Dermavant Sciences, INC. | $33.40 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $29.10 | 2024 | |
| Organon LLC | $23.86 | 2025 | Vtama |
| Dermira, INC. | $15.74 | 2021 | |
| Genentech USA, INC. | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.